Nutritional composition and nutritional food for improving premature delivery retinopathy

Abstract

The invention relates to the technical field of nutritional food, and particularly discloses a nutritional composition and nutritional food for improving premature delivery retinopathy. The nutritional composition for improving the premature delivery retinopathy is prepared from the following components in parts by mass: 50 to 800 parts of breast milk oligosaccharide, 1 to 70 parts of lactoferrin and 0.25 to 50 parts of animal bifidobacterium subsp. Lactis. The nutritional composition provided by the invention can improve the abundance of beneficial bacteria bifidobacteria in intestinal tracts, reduce the abundance of enterobacter, reduce the neovascularization area of pathological retina caused by high oxygen and reduce the area of a non-vascular region of the retina which is not developed maturely; the oxidation process is inhibited or prevented through the retina-intestinal axis bidirectional regulation effect, so that retinal cells are protected from oxidative stress injury, and the retina-intestinal axis compound can be used in the fields of formula foods for special medical purposes, health foods, infant formula foods, common foods and the like.

Description

Technical Field

[0001] The present invention relates to the technical field of nutritional foods, and particularly relates to a nutritional composition and a nutritional food for improving retinopathy of prematurity. Background Art

[0002] Retinopathy of prematurity (ROP) is a serious complication in premature infants, caused by the loss of normal blood vessels in the immature retina and the appearance of new pathological blood vessels and fibroplasia, and is more common in low-birth-weight infants and small-for-gestational-age premature infants. In recent years, thanks to the continuous improvement of the rescue, treatment and nursing levels of critically ill premature infants, the survival rates of extremely low-birth-weight infants and ultra-low-birth-weight infants have shown a linear upward trend. Among them, there are many extremely premature infants and ultra-low-birth-weight infants between 22 weeks and 24 weeks who have been successfully treated. However, with the increase in their survival rates, the incidence of retinopathy of prematurity is also increasing year by year.

[0003] The treatment of retinopathy of prematurity is mostly surgical treatment and non-surgical treatment. Surgical treatments include laser photocoagulation, scleral buckling, vitrectomy, etc. Among non-surgical treatments, anti-VEGF (vascular endothelial growth factor) drugs are the most commonly used. At present, in the field of foods for premature infants and low-birth-weight infants, such as special medical purpose formula powder, infant formula powder, complementary foods and nutritional supplements, etc., there is no existing technology that can inhibit or prevent the oxidation process through the two-way regulation of the retina-gut axis and thus protect retinal cells from oxidative stress damage. Summary of the Invention

[0004] Aiming at the problem of how to improve retinopathy of prematurity, the present invention provides a nutritional composition and a nutritional food for improving retinopathy of prematurity. By controlling the components and their dosages of the nutritional composition, the retinopathy problem of premature infants and low-birth-weight infants can be significantly improved.

[0005] To solve the above technical problems, the technical solution provided by the present invention is: In a first aspect, the present invention provides a nutritional composition for improving retinopathy of prematurity, comprising the following components in parts by mass: 50 parts to 800 parts of human milk oligosaccharide, 1 part to 70 parts of lactoferrin, and 0.25 part to 50 parts of Bifidobacterium animalis subsp. lactis.

[0006] Compared with the prior art, the nutritional composition for improving retinopathy of prematurity provided by the present invention can inhibit or prevent the oxidation process through the two-way regulation of the retina-gut axis and thus protect retinal cells from oxidative stress damage. Test data show that the nutritional composition provided by the present invention can increase the abundance of the beneficial bacterium Bifidobacterium in the intestine, reduce the abundance of Enterobacter, and at the same time reduce the area of new blood vessels in the pathological retina caused by hyperoxia and reduce the area of avascular regions in the immature retina.

[0007] Preferably, the nutritional composition comprises the following components in parts by mass: 60 to 500 parts of human milk oligosaccharide, 5 to 50 parts of lactoferrin, and 1 to 30 parts of Bifidobacterium animalis subsp. lactis.

[0008] More preferably, the nutritional composition comprises the following components in parts by mass: 60 to 150 parts of human milk oligosaccharide, 5 to 20 parts of lactoferrin, and 1 to 10 parts of Bifidobacterium animalis subsp. lactis.

[0009] Even more preferably, the nutritional composition comprises the following components in parts by mass: 60 to 100 parts of human milk oligosaccharide, 8 to 12 parts of lactoferrin, and 3 to 7 parts of Bifidobacterium animalis subsp. lactis.

[0010] Preferably, the human milk oligosaccharide comprises at least one of 2'-fucosyllactose (2'-FL), lacto-N-neotetraose (LNnT), 3'-sialyllactose (3'-SL), or 6'-sialyllactose (6'-SL).

[0011] Preferably, the Bifidobacterium animalis subsp. lactis comprises at least one of Bb-12 strain, HN019 strain, or Bi-07 strain.

[0012] Preferably, the nutritional composition further comprises: protein, fat, and carbohydrate.

[0013] More preferably, the mass ratio of the human milk oligosaccharide to the carbohydrate is (1.4 to 15.6):100.

[0014] More preferably, the mass ratio of the lactoferrin to the protein is (0.07 to 5):100.

[0015] More preferably, the content of the Bifidobacterium animalis subsp. lactis is (0.002 to 0.5) g / 100 g.

[0016] More preferably, the nutritional composition further comprises the following components in parts by mass: 1000 to 2100 parts of protein, 2200 to 4100 parts of fat, and 4700 to 7000 parts of carbohydrate.

[0017] Even more preferably, the nutritional composition further comprises the following components in parts by mass: 1200 to 1700 parts of protein, 2500 to 3000 parts of fat, and 5000 to 5800 parts of carbohydrate.

[0018] More preferably, the protein comprises at least one of skim milk powder, isolated whey protein, concentrated whey protein, or concentrated milk protein.

[0019] Further preferably, the fat includes at least one of soybean oil, sunflower oil, coconut oil, rapeseed oil, corn oil or medium-chain triglycerides.

[0020] Further preferably, the carbohydrate includes at least one of desalted whey powder or lactose.

[0021] In a second aspect, the present invention provides a method for preparing the nutritional composition for improving retinopathy of prematurity, comprising the following steps: Weigh each component according to the designed mass ratio, and mix them evenly to obtain the nutritional composition for improving retinopathy of prematurity.

[0022] In a third aspect, the present invention provides a nutritional food, comprising the nutritional composition for improving retinopathy of prematurity.

[0023] The nutritional food is a formula food for special medical purposes, a health food, an infant formula food or a general food, etc.

[0024] Preferably, the nutritional food further includes vitamins and minerals.

[0025] Further preferably, the vitamins and minerals include components with the following contents: vitamin A 299 μg RE / 100 g - 3781 μg RE / 100 g, vitamin D 3 5 μg / 100 g - 47 μg / 100 g, vitamin E 3 mg α-TE / 100 g - 51 mg α-TE / 100 g, vitamin K 1 21 μg / 100 g - 139 μg / 100 g, vitamin B 1 299 μg / 100 g - 1538 μg / 100 g, vitamin B 2 406 μg / 100 g - 3161 μg / 100 g, vitamin B 6 182 μg / 100 g - 1062 μg / 100 g, vitamin B 120.5 μg / 100 g to 8 μg / 100 g, niacin 1.5 mg / 100 g to 25.5 mg / 100 g, folic acid 53 μg / 100 g to 459 μg / 100 g, pantothenic acid 2.1 mg / 100 g to 10.2 mg / 100 g, vitamin C 53 mg / 100 g to 363 mg / 100 g, biotin 3 μg / 100 g to 51 μg / 100 g, inositol 21 mg / 100 g to 378 mg / 100 g, sodium 107 mg / 100 g to 534 mg / 100 g, potassium 299 mg / 100 g to 918 mg / 100 g, copper 182 μg / 100 g to 1277 μg / 100 g, magnesium 26 mg / 100 g to 88 mg / 100 g, iron 2 mg / 100 g to 19 mg / 100 g, zinc 3 mg / 100 g to 14 mg / 100 g, manganese 26 μg / 100 g to 513 μg / 100 g, calcium 256 mg / 100 g to 1282 mg / 100 g, phosphorus 128 mg / 100 g to 641 mg / 100 g, iodine 53 μg / 100 g to 299 μg / 100 g, chlorine 256 mg / 100 g to 1153 mg / 100 g, selenium 10 μg / 100 g to 46 μg / 100 g, choline 36 mg / 100 g to 256 mg / 100 g, taurine 0 to 64 mg / 100 g, L-carnitine 6 mg / 100 g to 100 mg / 100 g, and nucleotides 12 mg / 100 g to 58 mg / 100 g.

[0026] The nutritional composition provided by the present invention can be applied to fields such as formula foods for special medical purposes, health foods, infant formula foods, and ordinary foods. All components of the nutritional food in the present invention can adopt a dry mixing process. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 It is a graph showing the sequence proportion of Enterobacter in the feces of young rats in each group of the present invention; Figure 2 It is a graph showing the sequence proportion of Bifidobacterium in the feces of young rats in each group of the present invention; Figure 3 It is a graph showing the proportion of the area of the avascular region in the retina of young rats in each group of the present invention; Figure 4 It is a graph showing the proportion of the area of the neovascular region in the retina of young rats in each group of the present invention; Figure 5 It is the SOD activity in the retina tissue of young rats in each group of the present invention; Figure 6 It is the MDA content in the retina tissue of young rats in each group of the present invention; In the figure, there is no significant difference between the same letters, and there is a significant difference between different letters (P < 0.05). Detailed implementation mode

[0028] In order to make the objectives, technical solutions and advantages of the present invention more clear and understandable, the present invention will be further described in detail below in conjunction with embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0029] In the present invention, materials without special instructions are all commercially available products. Among them, the producer of the Bb-12 strain is Chr. Hansen A / S, purchased from Hebei Chengxi Import and Export Trading Co., Ltd.; the producer of the HN019 strain is Danisco (China) Co., Ltd., purchased from Beijing Sharp Vision Technology Co., Ltd.; the producer of the Bi-07 strain is Danisco (China) Co., Ltd., purchased from Beijing Sharp Vision Technology Co., Ltd.

[0030] Example 1 This example provides a nutritional composition for improving retinopathy of prematurity, including the following components by mass: lacto-N-neotetraose (LNnT) 0.5 g, lactoferrin 0.01 g, Bifidobacterium animalis subsp. lactis (Bb-12 strain) 0.0025 g, protein (provided by equal mass of concentrated whey protein and concentrated milk protein) 14 g, fat (provided by equal mass of soybean oil and sunflower oil) 30 g, and carbohydrates (provided by equal mass of demineralized whey powder and lactose) 50 g.

[0031] Adopt the dry mixing process, and mix the components of the above nutritional composition for improving retinopathy of prematurity evenly.

[0032] Example 2 This example provides a nutritional composition for improving retinopathy of prematurity, including the following components by mass: 2'-fucosyllactose (2'-FL) 0.7 g, lactoferrin 0.1 g, Bifidobacterium animalis subsp. lactis (HN019 strain) 0.05 g, protein (provided by equal mass of skim milk powder and isolated whey protein) 14 g, fat (provided by equal mass of coconut oil, corn oil and medium-chain triglycerides) 27 g, and carbohydrates (provided by demineralized whey powder and lactose with a mass ratio of 5:1) 53 g. The total energy of protein, fat and carbohydrates is about 2138 kJ.

[0033] Adopt the dry mixing process, and mix the components of the above nutritional composition for improving retinopathy of prematurity evenly.

[0034] Example 3 This embodiment provides a nutritional composition for improving retinopathy of prematurity, comprising the following components by mass: human milk oligosaccharides (equal mass of 3'-SL and 6'-SL) 8 g, lactoferrin 0.7 g, Bifidobacterium animalis subsp. lactis (strain Bi-07) 0.5 g, protein (provided by equal mass of skim milk powder and concentrated milk protein) 17 g, fat (provided by equal mass of soybean oil, coconut oil and rapeseed oil) 25 g, and carbohydrate (provided by demineralized whey powder) 52 g.

[0035] Adopt the dry mixing process, and mix the components of the above nutritional composition for improving retinopathy of prematurity evenly.

[0036] Comparative Example 1 This comparative example provides a nutritional composition, which is similar to Example 2, except that: lactoferrin is replaced with the same mass of Bifidobacterium animalis subsp. lactis (strain Bi-07), that is, the dosage of Bifidobacterium animalis subsp. lactis (strain Bi-07) is 0.15 g. The remaining conditions are the same as those in Example 2 and will not be repeated.

[0037] Comparative Example 2 This comparative example provides a nutritional composition, which is similar to Example 2, except that: human milk oligosaccharides (2'-FL) are replaced with lactoferrin and Bifidobacterium animalis subsp. lactis (strain Bi-07), the dosage of lactoferrin is 0.5 g, and the dosage of Bifidobacterium animalis subsp. lactis (strain Bi-07) is 0.35 g. The remaining conditions are the same as those in Example 2 and will not be repeated.

[0038] Comparative Example 3 This comparative example provides a nutritional composition, which is similar to Example 2, except that: human milk oligosaccharides (2'-FL), lactoferrin and Bifidobacterium animalis subsp. lactis (strain Bi-07) are omitted simultaneously. The remaining conditions are the same as those in Example 2, that is, the nutritional composition comprises the following components by mass: protein (equal mass of skim milk powder and isolated whey protein) 14 g, fat (equal mass of coconut oil, corn oil and medium-chain triglycerides) 27 g, and carbohydrate (demineralized whey powder and lactose with a mass ratio of 5:1) 53 g. The total energy of protein, fat and carbohydrate is about 2138 kJ.

[0039] Application Examples 1 - 3 Application Examples 1 - 3 respectively provide a nutritional food, which consists of a nutritional composition for improving retinopathy of prematurity and vitamins and minerals. The nutritional composition respectively adopts the nutritional composition for improving retinopathy of prematurity in Examples 1 - 3. The vitamins and minerals comprise the following components: vitamin A 530 μg RE / 100 g, vitamin D 3 16 μg / 100 g, vitamin E 12 mg α-TE / 100 g, vitamin K1 35 μg / 100 g, vitamin B 1 700 μg / 100 g, vitamin B 2 1064 μg / 100 g, vitamin B 6 630 μg / 100 g, vitamin B 12 1.9 μg / 100 g, niacin 7.5 mg / 100 g, folic acid 150 μg / 100 g, pantothenic acid 5 mg / 100 g, vitamin C 110 mg / 100 g, biotin 18 μg / 100 g, inositol 88 mg / 100 g, sodium 290 mg / 100 g, potassium 501 mg / 100 g, copper 430 μg / 100 g, magnesium 50 mg / 100 g, iron 8.5 mg / 100 g, zinc 5.5 mg / 100 g, manganese 53 μg / 100 g, calcium 589 mg / 100 g, phosphorus 342 mg / 100 g, iodine 93 μg / 100 g, chlorine 440 mg / 100 g, selenium 12.8 μg / 100 g, choline 83 mg / 100 g, taurine 33 mg / 100 g, L-carnitine 10.8 mg / 100 g, and nucleotides 21 mg / 100 g.

[0040] Adopt the dry mixing process, and mix the components of the above nutritional food evenly.

[0041] Apply Comparative Examples 1 - 3 Comparative Examples 1 - 3 respectively provide a nutritional food, which consists of a nutritional composition and vitamins and minerals. The nutritional compositions respectively adopt the nutritional compositions of Comparative Examples 1 - 3. The components and contents of the vitamins and minerals are the same as those in Application Example 1 and will not be elaborated here.

[0042] Adopt the dry mixing process, and mix the components of the above nutritional food evenly.

[0043] Efficacy test (1)Establishment and grouping of animal models Healthy adult pregnant SD rats were selected for the experiment, provided by Spf (Suzhou) Biotechnology Co., Ltd. (China), with the certificate number SCXK (Su) 2022 - 0006, gestational age of 12 d - 14 d, and body weight of 450 g - 550 g. Before the experiment, each pregnant rat was placed in a separate mouse cage to adapt to the environment for 3 d - 5 d, with free access to water and food. The experimental environmental conditions included: light / dark cycle of 12 h / 12 h, background noise of 40 db ± 10 db, and room temperature of 20°C - 24°C. The gestation period of normal rats is 19 d - 23 d, and the pups born before the 20th day of pregnancy were defined as premature pups.

[0044] Pregnant rats were used to establish a preterm birth model with lipopolysaccharide (LPS) to induce preterm birth. On the 16th day of pregnancy, the mass of pregnant rats was accurately weighed, and LPS (purchased from Thermo Fisher Scientific) was intraperitoneally injected at a dose of 350 μg / kg for 2 consecutive days.

[0045] 10 - 12 preterm pups per litter were included in the subsequent experiment, with a total of 60 - 70 pups. They were randomly divided into 6 groups, with 10 pups in each group. Each group was fed for 30 days, and the feed formulas for each group were the nutritional foods of Application Examples 1 - 3 and Application Comparative Examples 1 - 3, respectively.

[0046] Within 6 hours after the preterm pups were born, the newborn preterm pups were placed in a sealed oxygen chamber with an oxygen concentration of 80% (hyperoxia) in the chamber, which was alternated every 24 hours for 14 days. At 15 days, the pups were placed in normal air and continued to be raised until 30 days after birth. A digital oxygen meter was used to monitor the oxygen concentration in the oxygen chamber, with at least 5 measurements per day. The oxygen flow rate was 2 L / min - 3 L / min, and the nitrogen flow rate was 0.5 L / min - 0.8 L / min, so that the oxygen concentration in the oxygen chamber during the hyperoxia period was maintained at 80% ± 2%.

[0047] (2)16S rRNA sequencing of fecal intestinal flora On the 30th day of feeding, feces of the six groups of pups were collected respectively. Before each collection of feces, each pup was placed alone in a sterilized animal cage box and allowed to move freely for 30 minutes. Approximately 0.2 g of feces from each pup was collected, and bacterial DNA in the feces of each group of pups was extracted according to the instructions of the QIAGEN fecal genomic DNA extraction kit. Then, universal primers 341F and 805R were used for PCR amplification in the highly variable region of 16S rRNA V3 - V4. After quantitative detection of the amplified products by 2% agarose gel electrophoresis, high - throughput sequencing of the 16S rRNA gene was performed to obtain the proportion of Escherichia coli and Bifidobacterium sequences. The test results are as Figures 1 to 2 and Table 1 shows.

[0048] Table 1 Proportion of Escherichia coli and Bifidobacterium sequences in the feces of pups in each group

[0049] In each column of Table 1, there is no significant difference between the same letters, and there is a significant difference between different letters (P < 0.05).

[0050] It can be seen from Figure 1 and Table 1 that the proportion of Escherichia coli sequences in the Application Comparative Example 3 group is the highest, followed by the Application Comparative Example 1 - 2 groups with no significant difference between the two groups. The Application Example 3 group is the lowest, and there is no significant difference among the Application Example 1 - 3 groups. Figure 2As can be seen from Table 1, the proportion of Bifidobacterium sequences in the application comparative example 3 group is the lowest, followed by the application comparative example 1-2 groups, and the difference between the two groups is not significant. The proportion of Bifidobacterium sequences in the application example 1-3 groups is higher than that in the application comparative example 1-3 groups, and there is a significant difference from the application comparative example 1-3 groups. The difference between the application example 1-3 groups is not significant. This indicates that the nutritional composition provided by the present invention can reduce the number of Enterobacter and increase the number of Bifidobacterium, thereby effectively improving the retinopathy of premature infants through microbial regulation.

[0051] (3)Area of avascular area and neovascular area in the retina of young rats After 30 days of feeding, the young rats in each group were sacrificed, and one eye was randomly selected to remove the residues in the retina and the residual vitreous vessels to make a retinal spread. The retinal spread was placed on a polylysine-coated glass slide with the inner layer of the retina facing up, sealed with glycerol at a concentration of 50%, covered with a coverslip, and stored in the dark at 4°C.

[0052] Stain the blood vessels, observe the stained spread under a fluorescence microscope and take pictures. The retinal blood vessels are green fluorescence, and the avascular area is the black area where the peripheral green fluorescence terminates. Measure and calculate the percentage of the avascular area, neovascular area and total retinal area through Adobe Photoshop CS3 image analysis software. The test results are as Figures 3 to 4 and Table 2 show.

[0053] Table 2 Results of the proportion of avascular area and neovascular area in the retina of young rats in each group

[0054] In each column of Table 2, there is no significant difference between the same letters, and there is a significant difference between different letters (P < 0.05).

[0055] From Figure 3 and Table 2, it can be seen that the proportion of the avascular area in the application example 1-3 groups is smaller than that in the application comparative example 1-3 groups, and the application comparative example 3 group is the highest, and there is a significant difference from the application comparative example 1-2 and application example 1-3 groups. From Figure 4 and Table 2, it can be seen that the proportion of the neovascular area in the application example groups 1-3 is smaller than that in the application comparative example 1-3 groups, and the application comparative example 3 group is the highest. This indicates that the nutritional composition provided by the present invention can effectively reduce the avascular area of the immature retina and reduce the pathological neovascular hyperplasia caused by hyperoxia.

[0056] (4)Determination of oxidative stress markers The retinal blood vessels of premature infants are not fully developed. High oxygen can cause vasoconstriction of immature retinas, leading to retinal hypoxia-ischemia, vascular occlusion, and then the production of a large number of vascular growth factors. Driven by the retinal VEGF signaling pathway, pathological retinal neovascularization and fibrous tissue hyperplasia form, and then retinal detachment occurs, resulting in blindness. Oxidative stress is one of the important injury mechanisms of ROP. The oxidative stress level of premature infants can be used as a predictor of ROP, and the degree of ROP lesions worsens with the increase in the degree of oxidative stress. Superoxide dismutase (SOD) and malondialdehyde (MDA) are very sensitive oxidative stress markers. Kits were used to measure the activity of SOD and the content of MDA. The SOD kit used a total superoxide dismutase (T-SOD) test kit (hydroxylamine method), and the MDA kit used a malondialdehyde (MDA) assay kit (TBA method), both purchased from Nanjing Jiancheng Bioengineering Institute.

[0057] Under a microscope, the retinas of the other eyes of the young rats in each group were quickly separated. According to the mass-volume ratio of retina to phosphate buffer (PBS buffer) of 1 g:9 mL, PBS buffer was added, and it was ground thoroughly to make a retinal homogenate. It was centrifuged at 3500 r / min for 10 min in a 4°C low-temperature centrifuge, and the supernatant was taken and stored at -80°C. The activity of SOD and the content of MDA in the retinal tissues of the young rats in each group were measured strictly according to the instructions of the SOD and MDA kits. The test results are as Figures 5 to 6 shown in Table 3.

[0058] Table 3 Test results of the activity of SOD and the content of MDA in the retinal tissues of the young rats in each group

[0059] In each column of Table 3, there is no significant difference between the same letters, and there is a significant difference between different letters (P < 0.05).

[0060] From Figure 5 and Table 3, it can be seen that the SOD activity of the Application Example 1-3 groups is higher than that of the Application Comparative Example 1-3 groups. The SOD activity of the Application Comparative Example 3 group is the lowest and is significantly different from other groups. From Figure 6 and Table 3, it can be seen that the MDA content of the Application Example 1-3 groups is significantly lower than that of the Application Comparative Example 1-3 groups. The MDA content of the Application Comparative Example 3 group is the highest and is significantly different from other groups. This shows that the intake of the nutritional composition provided by the present invention can effectively regulate the degree of oxidative stress.

[0061] The comprehensive results show that the nutritional composition provided by the present invention can inhibit or prevent the oxidation process through the bidirectional regulation of the retina-intestine axis, thereby protecting retinal cells from oxidative stress damage.

[0062] The above are only the preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions or improvements made within the spirit and principles of the present invention shall be included within the protection scope of the present invention.

Claims

1. A nutritional composition for improving retinopathy of prematurity, characterized in that: The invention comprises the following components in parts by weight: 50 to 800 parts of human milk oligosaccharides, 1 to 70 parts of lactoferrin and 0.25 to 50 parts of animal Bifidobacterium lactis subsp.

2. The nutritional composition for improving retinopathy of prematurity according to claim 1, characterized in that: The nutritional composition comprises the following components in parts by mass: 60 to 500 parts of human milk oligosaccharide, 5 to 50 parts of lactoferrin and 1 to 30 parts of animal Bifidobacterium lactis subsp.

3. The nutritional composition for improving retinopathy of prematurity according to claim 2, characterized in that: The nutritional composition comprises the following components in parts by mass: 60 to 150 parts of human milk oligosaccharide, 5 to 20 parts of lactoferrin and 1 to 10 parts of animal Bifidobacterium lactis subsp.

4. The nutritional composition for improving retinopathy of prematurity according to claim 1, characterized in that: The human milk oligosaccharide comprises at least one of 2'-fucosyllactose, lactose-N-neotetraose, 3'-sialyllactose or 6'-sialyllactose; The animal Bifidobacterium lactis subspecies includes at least one of the Bb-12 strain, the HN019 strain or the Bi-07 strain.

5. The nutritional composition for improving retinopathy of prematurity according to claim 1, characterized in that: The nutritional composition further comprises: protein, fat and carbohydrate.

6. The nutritional composition for improving retinopathy of prematurity according to claim 5, characterized in that: The mass ratio of the human milk oligosaccharide to the carbohydrate is (1.4-15.6):100; The mass ratio of the lactoferrin to the protein is (0.07-5):100; The content of the animal Bifidobacterium lactis subspecies is (0.002-0.5) g / 100 g.

7. The nutritional composition for improving retinopathy of prematurity according to claim 1, 5 or 6, characterized in that: The nutritional composition further comprises the following components in parts by mass: 1000 to 2100 parts of protein, 2200 to 4100 parts of fat and 4700 to 7000 parts of carbohydrate.

8. A nutritional food, characterized in that: A nutritional composition for improving retinopathy of prematurity comprising the nutritional composition according to any one of claims 1 to 7.

9. The nutritional food according to claim 8, characterized in that The nutritional food also includes vitamins and minerals.

10. The nutritional food according to claim 9, characterized in that The vitamins and minerals include the following components: vitamin A 299μg RE / 100g~3781μg RE / 100g, vitamin D3 5μg / 100g~47μg / 100g, vitamin E3mg α-TE / 100g~51mg α-TE / 100g, vitamin K1 21μg / 100g~139μg / 100g, vitamin B1 299μg / 100g~1538μg / 100g, vitamin B2 406μg / 100g~3161μg / 100g, vitamin B6 182μg / 100g~1062μg / 100g, vitamin B 12 0.5μg / 100g~8μg / 100g, niacin 1.5mg / 100g~25.5mg / 100g, folic acid 53μg / 100g~459μg / 100g, pantothenic acid 2.1mg / 100g~10.2mg / 100g, vitamin C 53mg / 100g~363mg / 100g, biotin 3μg / 100g~51μg / 100g, inositol 21mg / 100g~378mg / 100g, sodium 107mg / 100g~534mg / 100g, potassium 299mg / 100g~918mg / 100g, copper 182μg / 100g~1277μg / 100g, magnesium 26mg / 100g~88mg / 100g, iron 2mg / 100g~19mg / 100g, zinc 3mg / 100g~14mg / 100g, manganese 26μg / 100g~5 13μg / 100g, calcium 256mg / 100g~1282mg / 100g, phosphorus 128mg / 100g~641mg / 100g, iodine 53μg / 100g~299μg / 100g, chlorine 256mg / 100g~1153mg / 100g, selenium 10μg / 100g~46μg / 100g, choline 36mg / 100g~256mg / 100g, taurine 0~64mg / 100g, L-carnitine 6mg / 100g~100mg / 100g and nucleotides 12mg / 100g~58mg / 100g.

Images